ANDA 75067, held by Actavis Mid Atlantic. Cromolyn Sodium.
As of Nov 21, 2026, ANDA 75067 (Cromolyn Sodium), held by Actavis Mid Atlantic, was first approved by FDA on Jul 19, 1999, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 19, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cromolyn Sodium10MG/ML · solution;inhalation | Cromolyn Sodium | Discontinued |
| Jan 6, 2005 | Supplement 6Labeling | Approved | None posted |
| Feb 20, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Apr 3, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Mar 28, 2000 | Supplement 2Manufacturing | Approved | None posted |
| Mar 28, 2000 | Supplement 1Manufacturing | Approved | None posted |
| Jul 19, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters